Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 353-366

  Keane, Pearse A ^a   de Salvo, Gabriella ^b   Sim, Dawn A ^a   Goverdhan, Srini ^b   Agrawal, Rupesh ^a   Tufail, Adnan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amsler; Choroidal neovascularization; Detection; Hyperacuity; Optical coherence tomography

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; VERTEPORFIN;

AGE RELATED MACULAR DEGENERATION; AMSLER CHART; BRUCH MEMBRANE; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; DIET SUPPLEMENTATION; DISCIFORM SCAR FORMATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ELECTRONIC MEDICAL RECORD; ENTOPTIC PERIMETRY; GEOGRAPHIC ATROPHY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MACULAR MAPPING TEST; META ANALYSIS (TOPIC); MOBILE PHONE; OPHTHALMIC PERIMETER; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT MONITORING; PERIMETRY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PREFERENTIAL HYPERACUITY PERIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCAR FORMATION; SCREENING TEST; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW (TOPIC); TIME TO TREATMENT; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISCRIMINATION; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

EID: 84923177990     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S59012     Document Type: Review

References (82)

1. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–1167.
2. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153(2):209.e2.–213.e2.
3. Belkin M, Kalter-Leibovici O, Chetrit A, Skaat A. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2013; 155(2):404.
4. Mitchell P, Bressler N, Doan QV, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS One. 2014;9(6):e101072.
5. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for chor-oidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129(6):709–717.
6. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299.
7. Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. J Clin Invest. 2014;124(4):1430–1438.
8. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640–1642.
9. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137(3):496–503.
10. Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina. 2008;28(2):201–211.
11. Soubrane G, Coscas G, Français C, Koenig F. Occult subretinal new vessels in age-related macular degeneration. Natural history and early laser treatment. Ophthalmology. 1990;97(5):649–657.
12. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, Aisenbrey S, De Laey JJ, Heimann K. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol. 2000;84(3):239–243.
13. Balasubramanian SA, Krishna Kumar K, Baird PN. The role of proteases and inflammatory molecules in triggering neovascular age-related macular degeneration: basic science to clinical relevance. Transl Res. 2014;164(3):179–192.
14. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008; 115(1):116–126.
15. Schmier JK, Covert DW, Lau EC. Patterns and costs associated with progression of age-related macular degeneration. Am J Ophthalmol. 2012;154(4):675.e1.–681.e1.
16. Campa C, Harding SP, Pearce IA, Beare NA, Briggs MC, Heimann H. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye (Lond). 2010;24(10): 1585–1589.
17. Liu TY, Shah AR, Del Priore LV. Progression of lesion size in untreated eyes with exudative age-related macular degeneration: a meta-analysis using Lineweaver-Burk plots. JAMA Ophthalmol. 2013;131(3):335–340.
18. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfn therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no 1. Am J Ophthalmol. 2003;136(3):407–418.
19. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007; 114(2):246–252.
20. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007; 144(6): 850–857.
21. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122–129.
22. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092–1101.
23. Zarranz-Ventura J, Liew G, Johnston RL, et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014; 121(10):1966–1975.
24. Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol. 2005;40(3):313–319.
25. Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV. Time to frist treatment: the significance of early treatment of exudative age-related macular degeneration. Retina. 2012;32(7):1260–1264.
26. Canan H, Sızmaz S, Altan-Yaycıoğlu R, Sarıtürk C, Yılmaz G. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis. Clin Interv Aging. 2014;9:141–145.
27. Kandula S, Lamkin JC, Albanese T, Edward DP. Patients’ knowledge and perspectives on wet age-related macular degeneration and its treatment. Clin Ophthalmol. 2010;4:375–381.
28. Woo JH, Au Eong KG. Don’t lose sight of age-related macular degeneration: the need for increased awareness in Singapore. Singapore Med J. 2008;49(11):850–853.
29. Lau JT, Lee V, Fan D, Lau M, Michon J. Knowledge about cataract, glaucoma, and age related macular degeneration in the Hong Kong Chinese population. Br J Ophthalmol. 2002;86(10):1080–1084.
30. Müller A, Keeffe JE, Taylor HR. Changes in eye care utilization following an eye health promotion campaign. Clin Experiment Ophthalmol. 2007;35(4):305–309.
31. Crossland M, Rubin G. The Amsler chart: absence of evidence is not evidence of absence. Br J Ophthalmol. 2007;91(3):391–393.
32. Amsler M. Earliest symptoms of diseases of the macula. Br J Ophthalmol. 1953;37(9):521–537.
33. Marmor MF. A brief history of macular grids: from Thomas Reid to Edvard Munch and Marc Amsler. Surv Ophthalmol. 2000;44(4): 343–353.
34. Augustin AJ, Offermann I, Lutz J, Schmidt-Erfurth U, Tornambe P. Comparison of the original Amsler grid with the modifed Amsler grid: result for patients with age-related macular degeneration. Retina. 2005;25(4):443–445.
35. Mathew R, Sivaprasad S. Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration. Eye (Lond). 2012;26(3):389–393.
36. Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol. 1993;111(6):776–780.
37. Loewenstein A, Malach R, Goldstein M, et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology. 2003;110(5):966–970.
38. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol. 1986;104(4):513–514.
39. Zaidi FH, Cheong-Leen R, Gair EJ, et al. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey. Eye (Lond). 2004;18(5):503–508.
40. Yannuzzi LA. A modified Amsler grid. A self-assessment test for patients with macular disease. Ophthalmology. 1982;89(2):157–159.
41. Mutlukan E. Red dots visual field test with blue on yellow and blue on red macula test grid. Eye (Lond). 2006;20(4):506–508; author reply 8–9.
42. Wall M, Sadun AA. Threshold Amsler grid testing. Cross-polarizing lenses enhance yield. Arch Ophthalmol. 1986;104(4):520–523.
43. Wolfe KA, Sadun AA. Threshold Amsler grid testing in diabetic retin-opathy. Graefes Arch Clin Exp Ophthalmol. 1991;229(3):219–223.
44. Fink W, Sadun AA. Three-dimensional computer-automated threshold Amsler grid test. J Biomed Opt. 2004;9(1):149–153.
45. Nazemi PP, Fink W, Lim JI, Sadun AA. Scotomas of age-related macular degeneration detected and characterized by means of a novel three-dimensional computer-automated visual field test. Retina. 2005;25(4):446–453.
46. Almony A, Garg S, Peters RK, et al. Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. Br J Ophthalmol. 2005;89(5):569–574.
47. Nazemi PP, Fink W, Sadun AA, Francis B, Minckler D. Early detection of glaucoma by means of a novel 3D computer-automated visual field test. Br J Ophthalmol. 2007;91(10):1331–1336.
48. Kim JK, Fahimi A, Fink W, Nazemi PP, Nguyen D, Sadun AA. Characterizing ethambutol-induced optic neuropathy with a 3D computerautomated threshold Amsler grid test. Clin Experiment Ophthalmol. 2008;36(5):484–488.
49. Jivrajka RV, Kim JK, Fink W, Sadun AA, Sebag J. Quantitative analysis of central visual field defects in macular edema using three-dimensional computer-automated threshold Amsler grid testing. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):165–170.
50. Robison CD, Jivrajka RV, Bababeygy SR, Fink W, Sadun AA, Sebag J. Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-automated threshold Amsler grid testing. Br J Ophthalmol. 2011;95(10):1419–1423.
51. Westheimer G. The spatial sense of the eye. Proctor lecture. Invest Ophthalmol Vis Sci. 1979;18(9):893–912.
52. Enoch JM, Williams RA, Essock EA, Barricks M. Hyperacuity perim-etry. Assessment of macular function through ocular opacities. Arch Ophthalmol. 1984;102(8):1164–1168.
53. Lakshminarayanan V, Aziz S, Enoch JM. Variation of the hyperacuity gap function with age. Optom Vis Sci. 1992;69(6):423–426.
54. Goldstein M, Loewenstein A, Barak A, et al. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina. 2005; 25(3): 296–303.
55. Alster Y, Bressler NM, Bressler SB, et al. Preferential hyperacuity perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005;112(10):1758–1765.
56. Chew EY, Clemons TE, Bressler SB, et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design – HOME Study report number 1. Contemp Clin Trials. 2014;37(2):294–300.
57. Chew EY, Clemons TE, Bressler SB, et al. Randomized trial of a home monitoring system for early detection of choroidal neovasculariza-tion home monitoring of the Eye (HOME) study. Ophthalmology. 2014;121(2):535–544.
58. Querques G, Berboucha E, Leveziel N, Pece A, Souied EH. Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. Br J Ophthal-mol. 2011;95(7):986–991.
59. Querques G, Querques L, Rafaeli O, Canoui-Poitrine F, Bandello F, Souied EH. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2011; 52(9):7012–7018.
60. Wilkinson F, Wilson HR, Habak C. Detection and recognition of radial frequency patterns. Vision Res. 1998;38(22):3555–3568.
61. Wang YZ, Wilson E, Locke KG, Edwards AO. Shape discrimination in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002;43(6):2055–2062.
62. Wang YZ, He YG, Mitzel G, Zhang S, Bartlett M. Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci. 2013;54(8):5497–5505.
63. Kaiser PK, Wang YZ, He YG, Weisberger A, Wolf S, Smith CH. Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: results of a pilot study. Retina. 2013;33(9):1863–1870.
64. Trevino R, Kynn MG. Macular function surveillance revisited. Optom-etry. 2008;79(7):397–403.
65. Trevino R. Recent progress in macular function self-assessment. Ophthalmic Physiol Opt. 2008;28(3):183–192.
66. Trauzettel-Klosinski S, Biermann P, Hahn G, Weismann M. Assessment of parafoveal function in maculopathy: a comparison between the macular mapping test and kinetic manual perimetry. Graefes Arch Clin Exp Ophthalmol. 2003;241(12):988–995.
67. Bartlett H, Davies LN, Eperjesi F. The macular mapping test: a reliability study. BMC Ophthalmol. 2005;5:18.
68. Aulhorn E, Köst G. [White noise field campimetry. A new form of perimet-ric examination]. Klin Monbl Augenheilkd. 1988;192(4):284–288.
69. Schiefer U, Skalej M, Kolb M, et al. Lesion location influences perception of homonymous scotomata during fickering random dot pattern stimulation. Vision Res. 1998;38(9):1303–1312.
70. Freeman WR, El-Bradey M, Plummer DJ. Scanning laser entoptic perimetry for the detection of age-related macular degeneration. Arch Ophthalmol. 2004;122(11):1647–1651.
71. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254(5035):1178–1181.
72. Keane PA, Sadda SR. Retinal imaging in the twenty-first century: state of the art and future directions. Ophthalmology. 2014;121(12): 2489–2500.
73. Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012;57(5):389–414.
74. Do DV, Gower EW, Cassard SD, et al. Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC study. Ophthalmology. 2012;119(4):771–778.
75. Keane PA, Bhatti RA, Brubaker JW, Liakopoulos S, Sadda SR, Walsh AC. Comparison of clinically relevant findings from high-speed Fourier-domain and conventional time-domain optical coherence tomography. Am J Ophthalmol. 2009;148(2):242.e1.–248.e1.
76. Lu CD, Kraus MF, Potsaid B, et al. Handheld ultrahigh speed swept source optical coherence tomography instrument using a MEMS scanning mirror. Biomed Opt Express. 2013;5(1):293–311.
77. Grulkowski I, Liu JJ, Potsaid B, et al. Retinal, anterior segment and full eye imaging using ultrahigh speed swept source OCT with vertical-cavity surface emitting lasers. Biomed Opt Express. 2012;3(11):2733–2751.
78. Grulkowski I, Liu JJ, Zhang JY, et al. Reproducibility of a long-range swept-source optical coherence tomography ocular biometry system and comparison with clinical biometers. Ophthalmology. 2013; 120(11):2184–2190.
79. Walsh AC. Binocular optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2011;42(4):S95–S105.
80. Puliafto CA. OCT angiography: the next era of OCT technology emerges. Ophthalmic Surg Lasers Imaging Retina. 2014;45(5):360.
81. Schwartz DM, Fingler J, Kim DY, et al. Phase-variance optical coherence tomography: a technique for noninvasive angiography. Ophthalmology. 2014;121(1):180–187.
82. Jia Y, Bailey ST, Wilson DJ, et al. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2014;121(7):1435–1444.